TABLE 4.

Results of quantitative antigenemia in different settings

Setting	Reference	No. of patients	No. of PMN per slide/staining methoda	Level of antigenemia per slide in patients with CMV disease or syn- drome (mean or median)	Threshold considered high risk for disease requiring antiviral treatment (per slide or per 50,000 PMN)
Heart transplant	Koskinen et al. (99)	68	150,000/IP	500	100
	Grossi et al. (83)	294	200,000/IF
	All patients			385	200
	Recipient positive			366
	Recipient negative			450
	Ghisetti et al. (71)	30	200,000/IF	310	NRc
Liver transplant	van den Berg et al. (172)	45	150,000/IP	257b	>100
Kidney transplant	van den Berg et al. (174)	130	150,000/IP	54b	>10
	Halwachs et al. (85)	59	300,000/IP	>10	>10
Mixed solid-organ transplant	Niubo et al. (122)	127	200,000/IP	28–250	>20
Autologous marrow transplant	Boeckh et al. (19)	67	150,000/IF	>50	>5
Allogeneic marrow transplant	Boeckh et al. (12)	59	150,000/IF	NR	≥2
	Locatelli et al. (112)	48	200,000/IF	51	≥2
	Gondo et al. (74)	15	150,000/IP	>10	NR
HIV and AIDS	Gerna et al. (64)	52	200,000/IF	>100	NR
	Francisci et al. (59)	49	200,000/IF	59	NR
	Salzberger et al. (146)	144	50,000/APAAP
	Retinitis			28	NR
	Colitis			44	NR
	Esophagitis			171	NR
	Bek et al. (9)	144	200,000/IF	NR	>5
	Wetherill et al. (183)	22	100,000/IF	693	>48
	Reynes et al. (140)	138	200,000/IF	695	>100
	Dodt et al. (45)	200	50,000/APAAP	15d	NR
	Podzamczer (130)	241	200,000/IF	>20d	>20d

^aIP, immunoperoxidase staining; IF, immunofluorescence staining. 

^bNumbers are per 50,000 PMN (counted). 

^cNR, not reported. 

^dNumbers adjusted to number of cells per slide.